| Literature DB >> 34996748 |
Vivian L Weiss1, Yael K Heher2, Adam Seegmiller3, Paul A VanderLaan4, Michiya Nishino5.
Abstract
Patient safety and quality improvement initiatives are integral parts of every cytopathology laboratory. The need to revisit our approaches to patient safety are essential in light of the expanding test menu, ancillary studies, comprehensive diagnostic reports, and emergence of new technologies for augmenting cytologic diagnosis. Our interview with Drs. Yael Heher, Adam Seegmiller, and Paul VanderLaan explores recent developments that have shaped their perspectives in patient safety, test usage, and laboratory quality. The practical strategies presented provide tools for enhanced patient safety and improved outcomes in a new era of ancillary and molecular testing and standardized reporting in the cytopathology laboratory.Entities:
Keywords: Ancillary molecular testing; Cytopathology; Diagnostic management team; Pre-analytic error; Standardized reporting
Mesh:
Year: 2021 PMID: 34996748 PMCID: PMC8885884 DOI: 10.1016/j.jasc.2021.12.001
Source DB: PubMed Journal: J Am Soc Cytopathol ISSN: 2213-2953